secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127045
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q3 revenue $126K, down 27% YoY; net loss narrows to $1.4M
----------------------------------------------------------------------

- Revenue for nine months ended Sep 30, 2024: $600K, down 27% vs 2023 on 36% fewer units sold.
- Net loss in Q3 2024 was $1.4M vs $1.8M in Q3 2023; operating expenses cut $1.9M YTD.
- Cash at Sep 30: $2.2M; raised $775K net in Oct-Nov via stock sales.
- Completed Phase 1a optimization study for non-invasive VNS; partnered with Fletcher Spaght.
- Appointed Lisa Wolf as interim CFO effective Oct 1; supply chain redesigned for higher margins.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/0000950170-24-127045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017024127045/tivc-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer